TrialBlood2018

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.

Susan O'Brien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.